EU Insulin Battle Looms After EMA Panel Backs Novo’s Insulin Degludec
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top drug advisory panel, CHMP, gave backing to Novo Nordisk’s new long-acting insulin analog as well as to new therapies from Astellas and Savient for urinary incontinence and severe gout.